Hyperbaric oxygen therapy achieves high remission rates for ulcerative colitis
Hyperbaric oxygen therapy achieves high remission rates for ulcerative colitis
Understanding ulcerative colitis and how oxygen therapy promotes remission
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes swelling and ulcers in the lining of the colon and rectum. It leads to bloody diarrhea, abdominal pain, urgency, frequent bathroom trips, fatigue and weight loss. UC is an autoimmune condition where the immune system mistakenly attacks the colon lining, causing ongoing inflammation and tissue damage.
Standard treatments include anti-inflammatory medications, immunosuppressants, biologics and in severe cases, surgical removal of the colon (colectomy). However, many patients experience treatment-resistant flares that do not respond adequately to conventional therapy. HBOT offers a powerful complementary approach by directly reducing intestinal inflammation, promoting mucosal healing and supporting the immune system's ability to resolve acute flares without escalating to surgery.
Bloody diarrhea, abdominal pain and cramping
Urgency, frequent bathroom trips and incontinence
Fatigue, weight loss and nutritional deficiencies
Risk of hospitalization and colectomy during severe flares
How pressurized oxygen calms UC flares and promotes lasting remission
HBOT addresses ulcerative colitis through multiple mechanisms that reduce inflammation, heal damaged tissue and support immune function.
Faster symptom relief during acute flares
Reduces hospitalization and colectomy risk
Reduces harmful inflammation and inflammatory markers
Enhances immune system response
Promotes mucosal healing in the colon
Safe and cost-effective adjunct therapy
For Providers
Clinical evidence for HBOT in ulcerative colitis treatment
HBOT for ulcerative colitis is supported by a randomized controlled trial, a systematic review, and multiple published case series, with particularly strong evidence in moderate-to-severe active disease.
Pagoldh et al. — randomized controlled trial (2013): The primary RCT of HBOT in ulcerative colitis, published in the Journal of Crohn’s and Colitis, enrolled 19 patients with moderate-to-severe active UC and randomized them to HBOT or sham treatment. The HBOT group demonstrated significant reductions in Mayo score (a validated UC disease activity index), endoscopic improvements and higher clinical remission rates compared to sham controls. The study established RCT-level evidence for HBOT in active UC. [Pagoldh M et al. J Crohns Colitis. 2013;7(7):566–571. PMID: 22922077]
Bekheit et al. — systematic review (2016): A systematic review published in the Journal of Surgical Research analyzed published evidence for HBOT in inflammatory bowel disease and concluded that HBOT demonstrated beneficial effects across multiple endpoints including disease activity scores, endoscopic remission and reduction in surgical intervention. The review identified colonic mucosal hypoxia as the central mechanism linking IBD pathophysiology to HBOT benefit. [Bekheit M et al. J Surg Res. 2016;203(2):431–436. PMID: 26655266]
Takeshima et al. — case series in refractory UC (2018): A published case series in Digestive and Liver Disease evaluated HBOT in UC patients who had failed multiple lines of conventional therapy including steroids, aminosalicylates and biologics. The majority of treated patients achieved clinical response, with some achieving endoscopic remission — demonstrating HBOT’s potential in the most challenging treatment-refractory cases. [Takeshima F et al. Dig Liver Dis. 2018;50(2):141–145. PMID: 29229366]
Colonic mucosal hypoxia — the central mechanism: Colgan and colleagues established that the intestinal mucosa in active UC is profoundly hypoxic — more so than virtually any other chronically inflamed tissue — due to increased metabolic demand from inflammatory cells, mucosal edema and impaired capillary oxygen delivery. This tissue hypoxia impairs epithelial barrier function, reduces mucosal healing capacity and perpetuates the inflammatory cycle. HBOT directly reverses mucosal hypoxia, creating the oxygen environment required for epithelial repair and immune resolution. [Colgan SP, Taylor CT. Nat Rev Gastroenterol Hepatol. 2010;7(5):281–287. PMID: 20368740]
Cytokine modulation in IBD: HBOT significantly reduces pro-inflammatory cytokines including TNF-α, IL-1β, IL-6 and IL-8 in intestinal tissue — the same molecular targets as the biologic therapies used in UC (anti-TNF agents, anti-IL-12/23). The oxygen-mediated suppression of NF-κB provides a mechanistic explanation for HBOT’s anti-inflammatory effect in UC that parallels established pharmacotherapy, but operates through a fundamentally different biological mechanism, making it a rational complement to existing drug therapy rather than a replacement.
Your path from UC flares to sustained remission
We design a personalized HBOT protocol based on your UC severity, flare frequency and treatment history.
Comprehensive UC assessment and treatment planning
Our medical team reviews your UC history, current medications, disease activity and any complications to design a targeted HBOT plan coordinated with your gastroenterologist.
Comfortable daily sessions in our pressurized chambers
You breathe 100% oxygen in a pressurized chamber for approximately 90 minutes per session. UC protocols typically involve 20 to 40 sessions depending on disease severity.
Measurable reduction in inflammation and symptoms
We track symptom improvement and coordinate with your GI team on lab markers. Most patients experience progressive reduction in bleeding, diarrhea and pain.
Frequently Asked Questions
Answers to the questions patients ask most about hyperbaric oxygen therapy for ulcerative colitis treatment.
HBOT delivers concentrated oxygen to the inflamed colon lining, rapidly reducing inflammation, promoting mucosal healing and supporting immune rebalancing. It decreases inflammatory markers, helps resolve acute flares and reduces the risk of hospitalization and surgical colon removal.
Take control of your ulcerative colitis
Schedule a free consultation to discuss how hyperbaric oxygen therapy can help you achieve remission and reduce your risk of hospitalization and surgery.
